Boston Scientific price target raised to $57 from $56 at BTIG

BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific to $57 from $56 and keeps a Buy rating on the shares. For Q2, BTIG expects revenue growth just above the midpoint of the guidance range and an 80 bps sequential step-up in operating margin to model at the midpoint of the range for adjusted EPS, and anticipates good performance from outpatient procedures as well as the Electrophysiology, Interventional Cardiology, and Watchman segments, the analyst tells investors in a research note. The firm is bullish on Boston Scientific, but wonders whether expectations into the print are too high.